


IFW



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Claudio Soto-Jara

Serial No.: 10/726.366

Filed: December 3, 2003

For: PEPTIDE ANALOGS SUITABLE  
FOR IN VIVO USE IN THE TREATMENT  
OF DISEASES ASSOCIATED WITH  
ABNORMAL PROTEIN-FOLDING INTO  
AMYLOID, AMYLOID-LIKE DEPOSITS  
OR BETA-SHEET RICH PATHOLOGICAL  
PRECURSOR THEREOF

Examiner: To be assigned

Group Art Unit: 1647

Attorney Docket No.: 3154-6317.2US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

January 14, 2005  
Date

Signature

Aubry Blackburn

Name (Type/Print)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of U.S. patents are not being submitted pursuant to M.P.E.P. 609 III A(2). Copies of foreign patent documents and non-patent literature are enclosed pursuant to 37 C.F.R. § 1.98(a)(2).

U.S. Patent Documents

<u>U.S. Patent No.</u>	<u>Publication Date</u>	<u>Patentee</u>
US - 5,051,185	09-24-1991	Watanabe et al.
US - 5,216,127	06-01-1993	Hirai et al.
US - 5,230,996	07-27-1993	Rath et al.
US - 5,276,059	01-04-1994	Caughey et al.
US - 5,278,189	01-11-1994	Rath et al.
US - 5,449,663	09-12-1995	Bicher
US - 5,589,154	12-31-1996	Anderson
US - 5,624,908	04-29-1997	Bicher
US - 5,650,418	07-22-1997	Rath et al.
US - 5,700,447	12-23-1997	Bucala et al.
US - 5,733,524	03-31-1998	Bucala et al.
US - 5,733,933	03-31-1998	Bucala et al.
US - 5,780,615	07-14-1998	Bucala et al.
US - 5,801,200	09-01-1998	Bucala et al.
US - 5,869,534	02-09-1999	Bucala et al.
US - 5,935,927	08-10-1999	Vitek et al.
US - 5,958,883	09-28-1999	Snow
US - 6,001,331	12-14-1999	Caprathe et al.
US - 6,034,211	03-07-2000	Kelly
US - 6,037,327	03-14-2000	Castillo et al.
US- 6,037,458	03-14-2000	Hirai et al.
US- 6,136,548	10-24-2000	Anderson
US- 6,340,783 B1	01-22-2002	Snow
US- 6,399,314 B1	06-04-2002	Krishnamurthy
US- 6,410,598 B1	06-25-2002	Vitek et al.
US- 6,436,969 B1	08-20-2002	Khalifah et al.
US- 6,462,171 B1	10-08-2002	Soto-Jara et al.

**Attorney Docket No.: 3154-6317.2US**

US- 6,471,960 B1	10-29-2002	Anderson
US- 2002/0133019 A1	09-19-2002	Klunk et al.
US- 2002/0187157 A1	12-12-2002	Jensen et al.
US- 2003/0017995 A1	01-23-2003	Khalifah et al.
US- 2003/0050245 A1	03-13-2003	Gebbink et al.
US- 6,537,969 B1	03-25-2003	Blass
US- 2003/0072770 A1	04-17-2003	McAnalley et al.
US- 2003/0086938 A1	05-08-2003	Jensen et al.
US- 2003/0087407 A1	05-08-2003	Soto-Jara et al.
US- 2003/0109435 A1	06-12-2003	Prenner et al.
US- 2003/0118593 A1	06-26-2003	Dan et al.
US- 2003/0176365 A1	09-18-2003	Blass
US- 2003/0236391 A1	12-25-2003	Klunk et al.

Foreign Patent Documents

<u>Document No.</u>	<u>Publication Date</u>	<u>Patentee</u>
DE 197 35 902 A1	02-25-1999	Imtec Immundiagnostika GmbH
0 234 051	09-02-1987	Stichting Centraal Laboratorium
0 319 144 A1	06-07-1989	Asahi Kasel Kogyo Kabushiki Kalsha
0 494 848 A1	07-15-1992	Kabi Pharmacia AB
EP 1 130 031 A1	09-05-2001	Universitair Medisch Centrum Utrecht
EP 1 179 588 A1	02-13-2002	Matsumoto
WO 91/18610	12-12-1991	Olle Ljungqvist Medical AB
WO 91/19488	12-26-1991	Rath et al.
WO 92/11847	07-23-1992	Kabi Pharmacia AB

**Attorney Docket No.: 3154-6317.2US**

WO 94/01116	01-20-1994	The Government of the United States
WO 94/28909	12-22-1994	Bicher
WO 95/20979	08-10-1995	Picower Institute for Medical Research
WO 96/15799	05-30-1996	Rutgers, The State University of New Jersey
WO 96/39834	12-19-1996	New York University
WO 97/26919	07-31-1997	Warner-Lambert Company
WO 97/46547	12-11-1997	Texas A & M University System
WO 98/06418	02-19-1998	Mannatech, Inc.
WO 99/02545	01-21-1999	Novopharm Biotech Inc.
WO 99/09999	03-04-1999	University of Washington
WO 99/21565	05-06-1999	Cornell Research Foundation, Inc.
WO 00/59493	10-12-2000	Kansas University Medical Center
WO 00/66717	11-09-2000	Matsumoto
WO 00/68263	11-16-2000	Neurochem, Inc.
WO 01/07474 A1	02-01-2001	Stott
WO 01/12598 A2	02-22-2001	Trustees of Columbia University
WO 01/50134 A2	07-12-2001	American Cyanamid Co.
WO 01/58476 A2	08-16-2001	European Molecular Biology Laboratory
WO 01/62284 A2	08-30-2001	M & E Biotech A/S
WO 01/62799 A2	08-30-2001	Universitair Medisch Centrum Utrecht

**Attorney Docket No.: 3154-6317.2US**

WO 02/16333 A2	02-28-2002	University of Pittsburgh
WO 03/006893 A2	01-23-2003	Elan Pharmaceuticals, Inc.
WO 2004/004698 A2	01-15-2004	Universitair Medisch Centrum Utrecht

Other Documents

PCT International Search Report, PCT/NL2003/000501, dated March 31, 2004.

This Supplemental Information Disclosure Statement is believed to be filed before the mailing date of a first Office Action on the merits; therefore, no fee is due.

Respectfully submitted,



G. Scott Dorland  
Registration No. 51,622  
Attorney for Applicant(s)  
TRASKBRITT, P.C.  
P.O. Box 2550  
Salt Lake City, Utah 84110-2550  
Telephone: 801-532-1922

Date: January 10, 2005  
GSD/alb

Enclosures: Form PTO/SB/08  
Cited Documents

Document in ProLaw



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Sheet 1 of 4

Application Number	10/726,366
Filing Date	December 3, 2003
First Named Inventor	Claudio Soto-Jara
Group Art Unit	1647
Examiner Name	To be assigned
Attorney Docket Number	3154-6317.2US

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		US-5,051,185	09-24-1991	Watanabe et al.	
		US- 5,216,127	06-01-1993	Hirai et al.	
		US- 5,230,996	07-27-1993	Rath et al.	
		US- 5,276,059	01-04-1994	Caughey et al.	
		US- 5,278,189	01-11-1994	Rath et al.	
		US- 5,449,663	09-12-1995	Bicher	
		US- 5,589,154	12-31-1996	Anderson	
		US- 5,624,908	04-29-1997	Bicher	
		US- 5,650,418	07-22-1997	Rath et al.	
		US- 5,700,447	12-23-1997	Bucala et al.	
		US- 5,733,524	03-31-1998	Bucala et al.	
		US- 5,733,933	03-31-1998	Bucala et al.	
		US- 5,780,615	07-14-1998	Bucala et al.	
		US- 5,801,200	09-01-1998	Bucala et al.	
		US- 5,869,534	02-09-1999	Bucala et al.	
		US- 5,935,927	08-10-1999	Vitek et al.	
		US- 5,958,883	09-28-1999	Snow	
		US- 6,001,331	12-14-1999	Caprathe et al.	
		US- 6,034,211	03-07-2000	Kelly	
		US- 6,037,327	03-14-2000	Castillo et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
		DE 197 35 902 A1	02-25-1999	Imtec Immundiagnostika GmbH		
		0 234 051	09-02-1987	Stichting Centraal Laboratorium		
		0 319 144 A1	06-07-1989	Asahi Kasei Kogyo Kabushiki Kaisha		
		0 494 848 A1	07-15-1992	Kabi Pharmacia AB		
		EP 1 130 031 A1	09-05-2001	Universitair Medisch Centrum Utrecht		
		EP 1 179 588 A1	02-13-2002	Matsumoto		
		WO 91/18610	12-12-1991	Olle Ljungqvist Medical AB		
		WO 91/19488	12-26-1991	Rath et al.		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/726,366
Filing Date	December 3, 2003
First Named Inventor	Claudio Soto-Jara
Group Art Unit	1647
Examiner Name	To be assigned
Attorney Docket Number	3154-6317.2US

Sheet 2 of 4

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		US- 6,037,458	03-14-2000	Hirai et al.	
		US- 6,136,548	10-24-2000	Anderson	
		US- 6,340,783 B1	01-22-2002	Snow	
		US- 6,399,314 B1	06-04-2002	Krishnamurthy	
		US- 6,410,598 B1	06-25-2002	Vitek et al.	
		US- 6,436,969 B1	08-20-2002	Khalifah et al.	
		US- 6,462,171 B1	10-08-2002	Soto-Jara et al.	
		US- 6,471,960 B1	10-29-2002	Anderson	
		US- 2002/0133019 A1	09-19-2002	Klunk et al.	
		US- 2002/0187157 A1	12-12-2002	Jensen et al.	
		US- 2003/0017995 A1	01-23-2003	Khalifah et al.	
		US- 2003/0050245 A1	03-13-2003	Gebbink et al.	
		US- 6,537,969 B1	03-25-2003	Blass	
		US- 2003/0072770 A1	04-17-2003	McAnalley et al.	
		US- 2003/0086938 A1	05-08-2003	Jensen et al.	
		US- 2003/0087407 A1	05-08-2003	Soto-Jara et al.	
		US- 2003/0109435 A1	06-12-2003	Prenner et al.	
		US- 2003/0118593 A1	06-26-2003	Dan et al.	
		US- 2003/0176365 A1	09-18-2003	Blass	
		US- 2003/0236391 A1	12-25-2003	Klunk et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
		WO 92/11847	07-23-1992	Kabi Pharmacia AB		
		WO 94/01116	01-20-1994	The Government of the United States		
		WO 94/28909	12-22-1994	Bicher		
		WO 95/20979	08-10-1995	Picower Institute for Medical Research		
		WO 96/15799	05-30-1996	Rutgers, The State University of New Jersey		
		WO 96/39834	12-19-1996	New York University		
		WO 97/26919	07-31-1997	Warner-Lambert Company		
		WO 97/46547	12-11-1997	Texas A & M University System		
		WO 98/06418	02-19-1998	Mannatech, Inc.		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT***(use as many sheets as necessary)*

Sheet

3

of

4

**Complete if Known**

Application Number	10/726,366
Filing Date	December 3, 2003
First Named Inventor	Claudio Soto-Jara
Group Art Unit	1647
Examiner Name	To be assigned
Attorney Docket Number	3154-6317.2US

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			

Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	WO 99/02545	01-21-1999	Novopharm Biotech Inc.		
	WO 99/09999	03-04-1999	University of Washington		
	WO 99/21565	05-06-1999	Cornell Research Foundation, Inc.		
	WO 00/59493	10-12-2000	Kansas University Medical Center		
	WO 00/66717	11-09-2000	Matsumoto		
	WO 00/68263	11-16-2000	Neurochem, Inc.		
	WO 01/07474 A1	02-01-2001	Stott		
	WO 01/12598 A2	02-22-2001	Trustees of Columbia University		
	WO 01/50134 A2	07-12-2001	American Cyanamid Co.		
	WO 01/58476 A2	08-16-2001	European Molecular Biology Laboratory		
	WO 01/62284 A2	08-30-2001	M & E Biotech A/S		
	WO 01/62799 A2	08-30-2001	Universitair Medisch Centrum Utrecht		
	WO 02/16333 A2	02-28-2002	University of Pittsburgh		
	WO 03/006893 A2	01-23-2003	Elan Pharmaceuticals, Inc.		
	WO 2004/004698 A2	01-15-2004	Universitair Medisch Centrum Utrecht		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				Application Number	10/726,366
				Filing Date	December 3, 2003
				First Named Inventor	Claudio Soto-Jara
				Group Art Unit	1647
				Examiner Name	To be assigned
				Attorney Docket Number	3154-6317 21US
Sheet	4	of	4		

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

+